Nucleos(t)ide analogs improve long‐term prognosis in patients with chronic hepatitis B‐associated liver failure

Hu, Ting; Yao, Lipeng; Hu, Airong; Jiang, Suwen; Hao, Ying; Deng, Qinzhi; Hu, Yaoren; Zhou, Wenhong; Xiong, Tao

doi:10.1111/hepr.12755

Cited by 3 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our country, hepatitis B virus (HBV) infection is the main cause of acute-on-chronic liver failure (ACLF) [3], the mortality of which is as high as 62.18%–72.3% [4–6]. Other causes of ACLF include alcohol, drugs and toxic substances, and genetic metabolism.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Treatment of 3 Patients with Acute-on-Chronic Liver Failure

Lei

Zeng

et al. 2018

Case Reports in Medicine

View full text Add to dashboard Cite

Acute-on-chronic liver failure (ACLF) is an acute liver decompensation that occurs within 4 weeks on the basis of chronic liver disease. At present, the treatments of ACLF include general supportive treatment, etiological treatment, prevention and treatment of complications, artificial liver treatment, and liver transplantation. Many studies suggest that stem cell therapy may become a new treatment for patients with ACLF. Our department has also tried the application of this treatment. Now, there are three cases of stem cell therapy for patients with ACLF by our department which will be briefly reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Treatment of 3 Patients with Acute-on-Chronic Liver Failure

Lei

Zeng

et al. 2018

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…However, sustained reduction in viral load by antiviral therapy correlates strongly with lower risk of disease progression, and improvements in liver histopathology and clinical features . Several clinical studies have reported that nucleos(t)ide analogs (NAs) can effectively suppress viral replication and reduce disease progression in patients with HBV‐related cirrhosis, and concluded that treatment with these agents can induce regression of cirrhosis and reduction/prevention of cirrhosis‐related complications …”

Section: Introductionmentioning

confidence: 99%

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus‐related cirrhosis

Nagaoki

Aikata

Daijyo

et al. 2017

Hepatology Research

View full text Add to dashboard Cite

show abstract

Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography

Wang

et al. 2020

Nuclear Medicine Communications

View full text Add to dashboard Cite

Objectives Hepatosplenic radionuclide angiography is a relatively noninvasive method for evaluating hepatic portal perfusion. We used hepatosplenic radionuclide angiography to assess the effects of nucleo(s)tide analogs therapy on patients with chronic hepatitis B (CHB). Patients and methods A retrospective analysis was performed on patients who underwent hepatosplenic radionuclide angiography from January 2012 to May 2017 at the First Affiliated Hospital, College of Medicine, Zhejiang University. The correlations between the results of routine laboratory tests and hepatic perfusion index (HPI) were evaluated. The Wilcoxon signed-rank test and one-way ANOVA of repeated measures were used to compare the HPIs of patients who received nucleo(s)tide analogs therapy. Results There is a positive correlation between HPI and cholinesterase and serum albumin (ALB) and a negative correlation between HPI and aspartate aminotransferase-to-platelet ratio index and bilirubin (TBiL). An improvement in HPI was observed in patients with an initial HPI <61% after nucleo(s)tide analogs therapy. Conclusions Hepatosplenic radionuclide angiography can reflect the functional reserve of the liver and monitor liver fibrosis indirectly. It can also comprehensively assess the effects of antiviral therapy on patients with CHB, and antiviral therapy is critical for the treatment of hepatitis.

show abstract

Nucleos(t)ide analogs improve long‐term prognosis in patients with chronic hepatitis B‐associated liver failure

Abstract: Antiviral therapy with NUCs may reduce the mortality rate and improve the long-term prognosis of patients with CHB-LF.

Cited by 3 publications

References 40 publications

Analysis of Treatment of 3 Patients with Acute-on-Chronic Liver Failure

Analysis of Treatment of 3 Patients with Acute-on-Chronic Liver Failure

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus‐related cirrhosis

Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography

Contact Info

Product

Resources

About